BTAI vs. KPTI, LFCR, CHRS, OGI, SKYE, RPTX, ADVM, GALT, KOD, and CGEN
Should you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Karyopharm Therapeutics (KPTI), Lifecore Biomedical (LFCR), Coherus BioSciences (CHRS), Organigram (OGI), Skye Bioscience (SKYE), Repare Therapeutics (RPTX), Adverum Biotechnologies (ADVM), Galectin Therapeutics (GALT), Kodiak Sciences (KOD), and Compugen (CGEN). These companies are all part of the "pharmaceutical products" industry.
Karyopharm Therapeutics (NASDAQ:KPTI) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, community ranking and risk.
Karyopharm Therapeutics presently has a consensus target price of $4.60, suggesting a potential upside of 373.98%. BioXcel Therapeutics has a consensus target price of $11.80, suggesting a potential upside of 926.09%. Given Karyopharm Therapeutics' higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than Karyopharm Therapeutics.
Karyopharm Therapeutics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500.
Karyopharm Therapeutics has higher revenue and earnings than BioXcel Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Karyopharm Therapeutics has a net margin of -104.18% compared to Karyopharm Therapeutics' net margin of -8,715.72%.
Karyopharm Therapeutics received 289 more outperform votes than BioXcel Therapeutics when rated by MarketBeat users. Likewise, 72.13% of users gave Karyopharm Therapeutics an outperform vote while only 67.32% of users gave BioXcel Therapeutics an outperform vote.
In the previous week, Karyopharm Therapeutics and Karyopharm Therapeutics both had 3 articles in the media. BioXcel Therapeutics' average media sentiment score of 0.97 beat Karyopharm Therapeutics' score of 0.72 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.
66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 4.3% of Karyopharm Therapeutics shares are owned by company insiders. Comparatively, 35.8% of BioXcel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Karyopharm Therapeutics beats BioXcel Therapeutics on 10 of the 15 factors compared between the two stocks.
Get BioXcel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioXcel Therapeutics Competitors List
Related Companies and Tools
